Article
Phase I/II study of GM-CSF DNA as an adjuvant for a multipeptide cancer vaccine in patients with advanced melanoma.
Molecular therapy : the journal of the American Society of Gene Therapy - 1 Dec 2008
Perales Miguel-Angel, Yuan Jianda, Powel Sarah, Gallardo Humilidad F, Rasalan Teresa S, Gonzalez Christina, Manukian Gregor, Wang Jian, Zhang Yan, Chapman Paul B, Krown Susan E, Livingston Philip O, Ejadi Samuel, Panageas Katherine S, Engelhorn Manuel E, Terzulli Stephanie L, Houghton Alan N, Wolchok Jedd D
Abstract excerpt
Granulocyte-macrophage colony-stimulating factor (GM-CSF) enhances immune responses by inducing proliferation, maturation, and migration of dendritic cells (DCs) as well as expansion and differentiation of B and T lymphocytes. The potency of DNA vaccines can be enhanced by the addition of DNA encoding cytokines, acting as molecular adjuvants. We conducted a phase I/II trial of human GM-CSF DNA in conjunction with...
Topics
- Adjuvants, Immunologic
- CD8-Positive T-Lymphocytes
- Cancer Vaccines
- Genetic Therapy
- Granulocyte-Macrophage Colony-Stimulating Factor
- Humans
- Melanoma
- Neoplasm Staging